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Abstract: The prognosis in prostate cancer depends on several clinical-morphological factors, such as Gleason
score, pTNM and preoperative PSA level. Reliable biological markers are being sought to supplement clinical-
morphological data in order to better predict prognosis and to select an individualized therapeutic option. The
aim of this study was a comparative analysis of the expression of biological markers, such as Hif-1a, bcl-2, p53,
Ki-67, cyclin D1 and CD44 in BPH and prostate cancer, as well as examining their association with standard
prognostic factors in prostate cancer. The immunohistochemical analysis was made on 82 formalin-fixed, paraf-
fin-embedded tissue blocks: 43 prostate cancer specimens derived from patients who had undergone radical
resection, and 39 prostate bioptates derived from patients with BPH. A positive correlation was demonstrated
between Gleason score and the expression of both Hif-1a (R = 0.32, p < 0.05) and Ki-67 (R = 0.30, p < 0.05).
Additionally, a negative correlation was demonstrated between tumor stage (pTNM) and bcl-2 expression
(R = –0.35, p < 0.05). Hif-1a as a hypoxia marker and Ki-67 as a proliferation marker, both correlated with
Gleason score, may constitute important additional prognostic indicators in prostate cancer patients.
(Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 3, pp. 452–457)
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Introduction
The search for biological markers of carcinogenesis is
one of the most important fields of contemporary stud-
ies aimed at detecting and treating prostate cancer.
These biological markers are expected to supplement
(or even partly replace) information on standard prog-
nostic and predictive indicators, such as preoperative
PSA level, Gleason score and clinical staging. The most
reliable and decisive biomarkers of an individual risk
of disease progression and a chance of successful treat-
ment could also indicate differences in biological pro-
files of both benign and malignant lesions, which would
be helpful in their differential diagnosis.
In order to make a comparative evaluation of pro-
cesses known to be crucial for carcinogenesis, such as
proliferation, hypoxia, apoptosis and cellular adhe-
sion, we conducted an immunohistochemical stain-
ing of their representative proteins in material de-
rived from patients with prostate cancer and benign
prostate hyperplasia (BPH).
The proliferation rate, a feature that has been
proven to be an unfavorable prognostic factor in many
cancers, was evaluated using its two widely known
indicators: Ki-67 (Mib-1) protein, which is expressed
by proliferating cells during all active phases of the
cell cycle, and cyclin D1, which is involved in control-
ling the G1/S phase [1–3].
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The contribution of hypoxia, a factor proven to
increase radioresistance and limit the efficacy of che-
motherapy, was estimated on the basis of the staining
of its endogenous marker: hypoxia-inducible factor
1a (Hif-a) [4–6]. The protein is a central mediator of
a cellular response to hypoxic conditions. It promotes
transcription of genes which are essential for tumor
progression and are responsible for both neoplastic
angiogenesis and local infiltration [7, 8].
Apoptosis was evaluated based on the staining of
two proteins: bcl-2 and p53. Bcl-2 is a factor respon-
sible for apoptosis inhibition [9], while p53 is a key
factor activating apoptosis in cases of unrepairable
DNA injury as a result of a broad-spectrum of stress-
ful agents (e.g. hypoxia or oncogene expression) [10].
Cellular adhesion, a feature connected with tu-
mor progression and an ability for metastasizing [11]
was studied using CD44 protein staining. CD44 gly-
coprotein performs the function of a cellular sur-
face receptor for hyaluronic acid, a glycoaminogly-
coside which takes part in cancer cell metastasizing
[12]. Three forms of CD44 have been identified: full
length (exons 1–20), standard (exons 1–5, 16–20) and
CD44v [13].
Material and methods
Patients. A retrospective immunohistochemical analysis
comprised 82 formalin-fixed, paraffin-embedded tissue
blocks derived from 43 prostate cancer patients who had
undergone radical resection and 39 prostate bioptates de-
rived from patients with BPH. The average age of prostate
cancer patients on the day of the operation was 64.4 ± 6.4
years (range 48–75 years), and of BPH patients it was 66.6 ±
± 7.1 years (range 51–80 years). The average preoperative
PSA level was 11.1 ± 7.0 ng/ml (range 3.31–39.90 ng/ml)
and 8.4 ± 4.4 ng/ml (range 1.0–21.3 ng/ml), respectively in
prostate cancer and BPH patients. The average Gleason
score was 6.2 ± 1.3 (range 3–9). The post-operative clinical
stage was T2N0M0 (pT2N0M0) in 21 patients and
pT3N0M0 in 22 patients.
Immunohistochemistry. The analysis was conducted with
the EnVision method using the EnVision+System HRP
(horseradish peroxidase, K 4001 and K 4002, Dako) kit and
adequate monoclonal antibodies. 5 μm-thick sections de-
rived from 10% formalin-fixed, paraffin-embedded tumors
were placed onto basic adhesive slides and incubated for
two hours at 60°C in a chamber thermostat. Then the sec-
tions were deparaffinized in xylene and rehydrated in de-
creasing ethanol dilutions. Endogenous enzymatic activity
of peroxidase was inhibited with 3% hydrogen peroxide so-
lution. Depending on which antibody, a microwave oven or
a water bath was used for the epitope retrieval. The first
method was used for such mouse monoclonal antibodies
as: anti-Hif-1a (clone H1 alpha67, Chemicon Internation-
al), anti-p53 (clone DO-7, Dako), anti-bcl-2 (clone 124,
Dako), anti-Ki-67 (clone MIB-1, Dako) as well as rabbit
monoclonal anti-cyclin D1 (clone SP4, Lab Vision). The
second method was used for mouse monoclonal anti-CD44
(clone DF1485-CD44s, Dako). Then the sections were in-
cubated with primary antibodies (1:100 for Hif-1a, p53, bcl-2
and Ki-67; 1:50 for cyclin D1 and CD44), and afterwards
with the EnVision+System HRP reagent. Chromogen DAB
(3,3 diaminobenzidine, K3468, Dako) was used to demon-
strate the examined cellular structures. Cell nuclei were
stained with hematoxylin (S 2020, Dako). As the last step,
the sections were hydrated in increasing ethanol dilutions,
cleared in xylene and mounted in medium (Consul Mount,
Thermo Shandon, Runcorn, UK).
Biomarkers assessment. All slides were reviewed by two
researchers (E.Ś. and H.A.) using a light microscope with
a micrometric insertion (Olympus, Poland). The viewing fields
were evaluated at 40-fold magnification of an objective lens.
At least 500 (max. 1,000) cells of prostate cancer and at least
300 BPH cells were counted in several (7–10) viewing fields
[14], which were selected randomly due to the homogenous
distribution of all studied staining products in both cancer
and BPH specimens. The results of nuclear (Hif-1a, p53,
Ki-67, cyclin D1), cytoplasmic (bcl-2) and membrane
(CD44) staining were shown in the form of labeling indices
(LI) interpreted as a percentage of positively stained cells
among a total number of examined cells. Additionally, in
case of nuclear staining of prostate cancer specimens for
HIF-1a, cyclinD1 and p53, the intensity of immunohis-
tochemical reaction and the percentage of the most intensely
stained nuclei were evaluated  based on the Remmele et al.
method [15] (Table 1). The final result (reaction intensity)
was presented as a product of these two parameters (0–12)
according to the scale: 0–2 = negative or low, 3–6 = mod-
erate and > 6 = high [16].
Statistics. An accordance of the variables distribution with
a normal distribution was verified with the Shapiro–Wilk
test. In case of samples of approximately normal distribu-
tion (patients’ age) the t-student test was used to compare
Table 1. Evaluation of the immunohistochemical reaction
intensity acc. to the Remmele et al. method [15]
Reaction intensity Percentage of
the stained nuclei
0 — no reaction 0 — no reaction
1 — low intensity reaction 1 — reaction in < 10% of cells
2 — moderate intensity 2 — reaction in 10–50% of cells
reaction
3 — high intensity reaction 3 — reaction in 51–80% of cells
4 — reaction in > 80% of cells
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mean values of the independent variables. In other cases
(biomarkers) a difference between the groups was analyzed
with the Mann–Whitney U test. The correlation between
the pairs of parameters was described by the Spearman’s
correlation coefficient. The p value < 0.05 was accepted as
the limit of statistical significance. The calculations were
performed using the commercial software package (Statis-
tica, StatSoft, Tulsa, OK, USA).
Results
A positive nuclear staining of Hif-1a was observed in
90.7% (39/43) of the tumors and in 12.8% (5/39) of
BPH. The level of hypoxia in the prostate cancer
group was significantly higher than in the BPH group
(LI: 16.1 ± 13.8 and 0.61 ± 2.55, respectively;
p < 0.001) (Figures 1A1, A2). A cytoplasmic Hif-1a
staining was also occasionally observed but was not
considered in the analysis. The low intensity reaction
(1–2) was observed in 17 tumors (39.6%) and moder-
ate intensity reaction (3–6) in 22 tumors (51.1%). The
high intensity reaction was not observed. For the BPH
group, we did not present results based on the Rem-
mele method because a positive nuclear staining was
observed in only 12.8% of cases and the reaction in-
tensity was very low. A positive correlation was dem-
onstrated between Hif-1a labeling index and Glea-
son score (R = 0.32, p < 0.05; Figure 2). There was
no correlation between Hif-1a labeling index and the
other standard prognostic factors (i.e. PSA, pTNM).
A positive cytoplasmic reaction with anti-bcl-2 was
achieved in 39.5% of prostate cancers (17/43) and in
94.9% of BPH (37/39). Bcl-2 expression was significantly
higher among patients with BPH compared to those with
cancers (LI: 6.97 ± 16.42 and 26.21 ± 18.89, respective-
ly; p < 0.001) (Figures 1C1, C2). In the prostate cancer
group, there was a negative correlation between bcl-2
expression and pTNM (R = –0.35; p < 0.05; Figure 2).
A nuclear reaction with anti-p53 was observed in
69.8% of prostate cancers (30/43) and in 74.4% of BPH
(29/39). There was no significant difference of p53 ex-
pression between the groups (LI: 11.86 ± 19.51 and
2.03 ± 2.27, respectively; p > 0.05) (Figures 1F1, F2).
For most tumors (27/43), the expression intensity was
weak or moderate (2–6). An intense expression (9) was
observed in three cases and it comprised over 60% of
cancer cells. For the BPH group, we did not present
results based on the Remmele method because a pos-
itive nuclear staining was observed in a small number
of cells and the reaction intensity was very low. No sig-
nificant correlation was proven between p53 LI and
the standard prognostic factors of prostate cancer.
Ki-67 expression was observed in 93% (40/43) of
the tumors and in all BPH cases, while a nuclear re-
action for cyclin D1 was reported in 93% of prostate
Figure 1. Immunohistochemical staining of prostate cancer
and BPH. Nuclear: Hif-1a: A1 (LI: 16.1 ± 13.8),
A2 (LI: 0.61 ± 2.55); Ki-67: D1 (LI: 6.13 ± 5.41),
D2 (LI: 1.44 ± 0.99); Cyclin D1: E1 (LI:  9.89 ± 9.73),
E2 (LI: 5.31 ± 6.58); p53: F1 (LI: 11.86  ± 19.51),
F2 (LI: 2.03 ± 2.27). Cytoplasmic and membrane: CD44:
B1 (LI: 12.77 ± 16.52), B2 (LI: 3.94 ± 4.45). Cytoplasmic:
bcl-2: C1 (LI: 6.97 ± 16.42), C2 (LI: 26.21 ± 18.89). Original
magnification: × 100 (E1); × 200 (A2, B1, B2, C1, D1, E2, F1);
× 400 (A1, C2, D2, F2). Lower magnification in the case of
prostate cancer was chosen to better visualize a higher
percentage of positive immunohistochemical reaction in
cancer cells compared to BPH cells. Higher magnification in
the case of BPH was chosen to better visualize the type of
immunohistochemical reaction
A1 A2
B1 B2
C1 C2
D1 D2
E1 E2
F1 F2
cancers (40/43) and in 64.1% of BPH (25/39). Ki-67
expression for prostate cancers appeared to be high-
er than for BPH (Ki-67 LI: 6.13 ± 5.41 vs. 1.44 ±
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± 0.99, p < 0,001; cyclin D1 LI: 9.89 ± 9.73 vs. 5.31 ±
± 6.58, p < 0.01) (Figures 1D1, D2, E1, E2).
In the case of cyclin D1, a low intensity reaction
(1–2) was observed in 25 tumors (58.1%) and moder-
ate intensity reaction (3–6) in 15 tumors (34.9%). We
did not observe any high intensity reaction. For the
BPH group, we did not present results based on the
Remmele method because a positive nuclear stain-
ing was observed in a small number of cells and the
reaction intensity was very low.
A positive correlation between Ki-67 labeling in-
dex and Gleason score was noted (R = 0.30, p < 0.05;
Figure 2). In the BPH group, there was a significant
increase in Ki-67 LI with an increasing patient age
(R = 0.34, p < 0.05).
No correlation between cyclin D1 LI and the stan-
dard prognostic factors of prostate cancer was shown.
The percentage of tumors with a membrane or
cytoplasmic reaction for a presence of CD44 protein
was 86% (37/43). CD44 expression in the BPH group
was reported in 76.9% (30/39) of cases. The differ-
ence between the prostate cancer and BPH groups
was significant (LI: 12.77 ± 16.52 and 3.94 ± 4.45,
respectively; p < 0.01) (Figures 1B1, B2). There was
no correlation between CD44 LI and the standard
prognostic factors of prostate cancer.
Discussion
The literature regarding the biological factors affect-
ing a pathophysiological picture of both BPH and pros-
tate cancer is equivocal, and often contradictory.
Our study proved a significant difference in the
expression of the studied biological markers, includ-
ing Hif-1a, Ki-67, cyclin D1, CD44 (with the excep-
tion of p53), between BPH and prostate cancer.
Interestingly, at the same time, we did not observe
any significant difference in the preoperative PSA
level between the analyzed groups of patients. Addi-
tionally, PSA was the only standard prognostic factor
that did not show any relationship with the examined
biological parameters. Our findings define PSA as
a factor which is not correlated with prostate cancer bi-
ology, but only with a presence of any pathological pro-
cess in the prostate. As an organ-specific marker, it still
remains a valuable indicator of processes proceeding
with prostate architecture disturbances, including be-
nign nodular hyperplasia and prostatitis. Simultaneous-
ly, PSA is still the only broadly clinically exploited mon-
itor of the post-treatment course of prostate cancer [17].
The most significant differences of biomarkers
expression between the study groups were regarding
Hif-1a and Ki-67 (p < 0.001), which indicates a sig-
nificant role of hypoxia and cellular proliferation in
Figure 2. A. Positive correlation between Gleason score
and Hif-1a LI (R = 0.32, p < 0.05). B. Negative correla-
tion between pTNM and bcl-2 LI (R = –0.35, p < 0.05;
pTNM groups correspond to: 1 — pT2aN0M0;
2 — pT2bN0M0; 3 — pT2cN0M0; 4 — pT3aN0M0;
5 — pT3bN0M0; 6 — pT3cN0M0; 7 — pT3bN1miM0;
8 — pT3cN1M0). C. Positive correlation between
Gleason score and Ki-67 LI (R = 0.30, p < 0.05)
CI — confidence interval
A
B
C
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carcinogenesis and prostate cancer progression. The
correlation between the expression of these two pro-
teins and Gleason score might confirm this conclusion.
An increasing proliferation rate seems to promote both
a lower differentiation degree of cancer cells and a high-
er hypoxia degree of a growing tumor, not sufficiently
supplied with oxygen and nutrients by a pathological
net of vessels.
The literature data on a relationship between hy-
poxia and standard prognostic factors in prostate can-
cer is equivocal. Carnell et al. confirmed our results
[18], while Du et al. reported no correlation between
Hif-1a and clinical parameters [19]. Interchangeably
however, a high proliferative index in prostate can-
cer has been reported to be a factor associated with
radiotherapy failure, a higher risk of metastases and
a shorter recurrence-free survival [20, 21]. Interest-
ingly, our study showed a significant increase of Ki-67
expression with an increasing patient age in the BPH
group, suggesting a possibility of transformation from
BPH to prostate cancer through an escalation of the
proliferation process. We also observed significantly
higher cyclin D1 labeling indices in the prostate can-
cer group, although no correlation between the pro-
tein expression and the standard prognostic factors
was shown. Our observation is consistent with the
results of Aaltomaa et al. [22], but contrary to some
other authors’ reports of a relationship between cy-
clin D1 expression and both low preoperative PSA
level and high Gleason score [23]. The lack of high
intensity nuclear reaction and relatively low labeling
index for both cyclin D1 (meaning cells in the G1/S
phase) and Ki-67, might reflect a slow growth of the
studied tumors (none of them metastasized).
Our results suggest that cyclin D1 has a limited
value as a potential biomarker supporting the choice
of a therapeutic option, since it seems to be mainly
expressed in advanced prostate cancers. Our findings
are consistent with Drobnjak et al. [24], who found
a higher cyclin D1 expression in prostate cancer pa-
tients with bone metastases compared to those with-
out cancer dissemination.
The results of bcl-2 and p53 staining did not give
an unequivocal description of the apoptosis process
in either BPH or prostate cancer. We noted a signifi-
cantly higher bcl-2 expression in the BPH group com-
pared to the cancer group. The negative correlation
of the protein expression with pTNM might suggest
its meaningful role in the early stage of the cancer.
Additionally, since there is a proven relationship be-
tween apoptosis and hypoxia, we cannot exclude that
an increasing (with tumor growth) hypoxia correlates
with a decreasing inhibition of apoptosis. Our find-
ings are contrary to the results of Bubendorf et al.
[25], who reported a high bcl-2 level in advanced pros-
tate cancer, and consistent with the observations of
Tolonen et al. [26] of a higher bcl-2 expression in PIN
(prostatic interepithelial neoplasia) than in prostate can-
cer. Additionally, we noted an increase in the level of
cyclin D1 with a decrease of bcl-2 expression (R =
= –0.32, p < 0.05), which suggests a modulation of cy-
clin D1 synthesis by bcl-2 protein and is consistent with
other authors’ results [27]. The results on the other apo-
ptosis-connected protein, p53, which did not show any
relationship with the standard prognostic factors or any
difference of expression between the groups, suggest that
the p53 tumor suppressor gene mutations do not influ-
ence a differentiation degree or clinical stage of pros-
tate cancer. Our findings confirmed the reports of
Karaburun et al. [28]. But they contradict the observa-
tions of Fonseca et al. [29] of a positive correlation be-
tween p53 expression and both an increasing PSA level
and clinical stage. We also noted a significant positive
correlation between p53 labeling index and Ki-67 label-
ing index (R = 0.35, p < 0.005), confirming that the
mutated gene p53 protein loses the ability to inhibit cell
proliferation. Our data is consistent with the results of
Amirghofran et al. [30] and Bergera et al. [31].
Cellular adhesion proteins, like CD44, belong to
the group of promising biomarkers and have been
widely analyzed in different types of cancers [32].
Although we showed a significant difference of CD44
immunoreactivity between the BPH and prostate can-
cer groups, no correlation between the protein expres-
sion and the standard prostate cancer prognostic indi-
cators was found. Our findings do not confirm the re-
sults of Aaltomaa et al. [33], who observed a negative
correlation between CD44 expression and Gleason
score, preoperative PSA level, and clinical stage.
We conclude that Ki-67 as a marker of prolifera-
tion, and Hif-1a as a hypoxia marker, are the most
reliable biological markers of prostate cancer and may
be useful in both differentiating from BPH and pre-
dicting answer for treatment (e.g. better outcome af-
ter high fraction doses of irradiation in cases of high-
ly hypoxic tumors) as well as prognosis (e.g. higher
probability of recurrence in cases of fast prolifera-
tion or high level of hypoxia). Because they are easily
estimated by immunohistochemical methods, they
may be applicable in everyday practice as an impor-
tant additional clinical tool.
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